



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-3228696
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I

Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 30/06/2016

(Rs in 000)

Particulars	3 months ended (30-06-2016)	Preceding 3 months ended (31-03-2016)	Corresponding 3 months ended in the previous year (30-06-2015)	Year to date figures for current period ended (30-06-2016)	Year to date figures for previous period ended (30-06-2015)	Previous year ended (31-03-2016)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue From Operations						
Net sales or Revenue from Operations	30400.000	16099.000	46037.000	30400.000	46037.000	131102.000
Other operating revenues	561.000	817.000	559.000	561.000	559.000	3711.000
Total Revenue from operations (net)	30961.000	16916.000	46596.000	30961.000	46596.000	134813.000
2 Expenses						
(a) Cost of materials consumed	23292.000	11328.000	38874.000	23292.000	38874.000	88047.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	504.000	-1948.000	0.000	504.000	0.000	-1947.000
(d) Employee benefit expense	2596.000	2564.000	2270.000	2596.000	2270.000	12092.000
(e) Depreciation and amortisation expense	1000.000	1051.000	800.000	1000.000	800.000	4101.000
(f) Other Expenses						
1 other expenses	1610.000	4683.000	2773.000	1610.000	2773.000	27759.000
Total other expenses	1610.000	4683.000	2773.000	1610.000	2773.000	27759.000
3 Profit (loss) from operations before other income, finance costs and exceptional items	29002.000	17678.000	44717.000	29002.000	44717.000	130952.000
4 Other income	1959.000	-762.000	1878.000	1959.000	1879.000	4761.000
5 Profit (loss) from ordinary activities before finance costs and exceptional items	1959.000	-762.000	1878.000	1959.000	1879.000	4761.000
6 Finance costs	536.000	471.000	553.000	536.000	553.000	2054.000
7 Profit (loss) from ordinary activities after finance costs but before exceptional items	1423.000	-1233.000	1326.000	1423.000	1326.000	2707.000
8 Prior period items before tax	0.000	0.000	0.000	0.000	0.000	-251.000
9 Exceptional items	0.000	0.000	0.000	0.000	0.000	0.000
10 Profit (loss) from ordinary activities before tax	1423.000	-1233.000	1326.000	1423.000	1326.000	2456.000
11 Tax Expense	200.000	-10.000	200.000	200.000	200.000	790.000
12 Net profit (loss) from ordinary activities after tax	1223.000	-1223.000	1126.000	1223.000	1126.000	1666.000
13 Extraordinary items	0.000	0.000	0.000	0.000	0.000	0.000
14 Net profit (loss) for the period	1223.000	-1223.000	1126.000	1223.000	1126.000	1666.000
15 Share of profit (loss) of associates	0.000	0.000	0.000	0.000	0.000	0.000
16 Profit (loss) of minority interest	0.000	0.000	0.000	0.000	0.000	0.000
17 Net Profit (loss) after taxes minority interest and share of profit (loss) of associates	1223.000	-1223.000	1126.000	1223.000	1126.000	1666.000
18 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
Reserves excluding revaluation reserve	15684.000	15684.000	14018.000	15684.000	14018.000	15684.000
20 Earnings per share						
i Earnings per share before extraordinary items						
Basic earnings per share before extraordinary items	0.241	0.000	0.220	0.241	0.220	0.328
Diluted earnings per share before extraordinary items	0.241	0.000	0.220	0.241	0.220	0.328
ii Earnings per share after extraordinary items						
Basic earnings per share after extraordinary items	0.241	0.000	0.220	0.241	0.220	0.328
Diluted earnings per share after extraordinary items	0.241	0.000	0.220	0.241	0.220	0.328

Notes:

- The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 11th July 2016.
- In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Company's financial results for the quarter ended June 30, 2016 there are no qualifications.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period exp. have been regrouped / rearranged, wherever necessary.
- Taxes and depreciation are calculated on proportionate basis on annual estimated basis.
- There were no investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended June 30, 2016.

Place : Indore
Date : 11.7.2016



For and behalf of the Board
Sanjay Sethi
Managing Director

**SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS**

4, Archana Apartment,
8-B, Ratlam Kothi, Indore - 452 001 (M.P.)
Ph: 2519439, 2527682
Mob No: 93021-23882
Email: scjainca2004@yahoo.com



LIMITED REVIEW REPORT

To
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh Indore(MP)


We have reviewed the accompanying statement of unaudited financial results of BERYL DRUGS LIMITED for the period ended 30/06/2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS**

FRN-004733C



(Signature)
(BADAL BANGUR)
PARTNER
M.No. 423724

Date: 11/07/2016
Place: Indore